{
  "id": 17918771,
  "title": "LG Chem revises licensing deal with US firm for obesity drug",
  "url": "https://urgent.news/2026/11/03/lg-chem-revises-licensing-deal-with-us-firm-for-obesity-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T06:07:03.000Z",
  "source": {
    "name": "The Korea Times",
    "slug": "the-korea-times",
    "url": "https://www.koreatimes.co.kr/business/companies/20261103/lg-chem-revises-licensing-deal-with-us-firm-for-obesity-drug"
  },
  "original_language": "en",
  "account": "LG Chem, the prominent South Korean chemical company, announced on Tuesday that it has revised the exclusive licensing deal it holds with the U.S.-based Rhythm Pharmaceuticals. This agreement pertains to the development and commercialization of an obesity treatment known as Bivamelagon. This investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist has seen its total contract value surge from $305 million to $855 million, according to a press release from LG Chem.\n\nThe company has already contributed $100 million to Rhythm under this agreement. Additional upfront payments amounting to $350 million are set to be made through 2029, the company disclosed. MC4R agonism has demonstrated the potential to significantly impact individuals struggling with hyperphagia and severe obesity associated with rare MC4R pathway diseases, as stated by Rhythm CEO David Meeker in a separate press release.\n\nMeeker emphasized that the company's commitment to this program highlights confidence in Bivamelagon's capacity to bring about meaningful benefits for patients and generate substantial long-term value for shareholders. LG Chem's objective is to expedite the availability of this innovative treatment for rare obesity-related disorders, as expressed in the company's statement.",
  "summary": "LG Chem, Korea's leading chemical company, said Tuesday it has amended an exclusive license agreement with the U.S.-based Rhythm Pharmaceuticals for the development and commercialization of an obesity treatment. The amendment covers Bivamelagon, an investigational oral small-molecule melanocortin-4 receptor (MC4R) agonist, increasing the total contract value from $305 million to $855 million, the…",
  "key_points": [
    "LG Chem revised licensing deal with Rhythm Pharmaceuticals for Bivamelagon.",
    "Total contract value increased from $305M to $855M.",
    "$350M in additional upfront payments set for 2029."
  ],
  "editors_take": "The massive increase in contract value signals LG Chem's aggressive commitment to securing a dominant position in the high-growth market for oral obesity treatments through its partnership with Rhythm Pharmaceuticals.",
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Yonhap News",
        "title": "LG Chem revises licensing deal with U.S. firm for obesity drug",
        "url": "https://urgent.news/2026/11/03/lg-chem-revises-licensing-deal-with-u-s-firm-for-obesity-drug",
        "published": "2026-11-03T05:42:24.000Z"
      },
      {
        "outlet": "Korea IT Times",
        "title": "LG Chem Expands Obesity Drug Licensing Deal with Rhythm Pharmaceuticals to $855 Million",
        "url": "https://urgent.news/2026/11/03/lg-chem-expands-obesity-drug-licensing-deal-with-rhythm",
        "published": "2026-11-03T06:08:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}